ID   AACT_HUMAN              Reviewed;         423 AA.
AC   P01011; B3KVQ7; Q13703; Q2TU87; Q2TU88; Q59GP9; Q6LBY8; Q6LDT7; Q6NSC9;
AC   Q8N177; Q96DW8; Q9UC47; Q9UNU9;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 2.
DT   07-APR-2021, entry version 239.
DE   RecName: Full=Alpha-1-antichymotrypsin;
DE            Short=ACT;
DE   AltName: Full=Cell growth-inhibiting gene 24/25 protein;
DE   AltName: Full=Serpin A3;
DE   Contains:
DE     RecName: Full=Alpha-1-antichymotrypsin His-Pro-less;
DE   Flags: Precursor;
GN   Name=SERPINA3; Synonyms=AACT; ORFNames=GIG24, GIG25;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6606438; DOI=10.1021/bi00291a001;
RA   Chandra T., Stackhouse R., Kidd V.J., Robson K.J.H., Woo S.L.C.;
RT   "Sequence homology between human alpha 1-antichymotrypsin, alpha 1-
RT   antitrypsin, and antithrombin III.";
RL   Biochemistry 22:5055-5061(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS BOCHUM-1 PRO-78 AND BONN-1
RP   ALA-252.
RX   PubMed=8244391; DOI=10.1006/geno.1993.1396;
RA   Poller W., Faber J.-P., Weidinger S., Tief K., Scholz S., Fischer M.,
RA   Olek K., Kirchgesser M., Heidtmann H.-H.;
RT   "A leucine-to-proline substitution causes a defective alpha 1-
RT   antichymotrypsin allele associated with familial obstructive lung
RT   disease.";
RL   Genomics 17:740-743(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-9.
RA   Kim J.W.;
RT   "Identification of a human cell growth inhibiting gene.";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-9.
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT THR-9.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANTS
RP   THR-9 AND ARG-267.
RC   TISSUE=Brain, Liver, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-46, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=3257719; DOI=10.1016/0092-8674(88)90462-x;
RA   Abraham C.R., Selkoe D.J., Potter H.;
RT   "Immunochemical identification of the serine protease inhibitor alpha 1-
RT   antichymotrypsin in the brain amyloid deposits of Alzheimer's disease.";
RL   Cell 52:487-501(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-423 (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Hippocampus;
RX   PubMed=9880565; DOI=10.1074/jbc.274.3.1821;
RA   Hwang S.-R., Steineckert B., Kohn A., Palkovits M., Hook V.Y.H.;
RT   "Molecular studies define the primary structure of alpha1-antichymotrypsin
RT   (ACT) protease inhibitor in Alzheimer's disease brains. Comparison of act
RT   in hippocampus and liver.";
RL   J. Biol. Chem. 274:1821-1827(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 22-86 AND 130-423 (ISOFORM 1).
RA   Rubin H.;
RL   Submitted (OCT-1989) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   PROTEIN SEQUENCE OF 24-34.
RX   PubMed=2787670; DOI=10.1016/0167-4838(89)90139-8;
RA   Lindmark B., Hilja H., Alan R., Eriksson S.;
RT   "The microheterogeneity of desialylated alpha 1-antichymotrypsin: the
RT   occurrence of two amino-terminal isoforms, one lacking a His-Pro
RT   dipeptide.";
RL   Biochim. Biophys. Acta 997:90-95(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-45.
RX   PubMed=7521171; DOI=10.1515/bchm3.1994.375.5.335;
RA   Korzus E., Luisetti M., Travis J.;
RT   "Interactions of alpha-1-antichymotrypsin, alpha-1-proteinase inhibitor,
RT   and alpha-2-macroglobulin with the fungal enzyme, seaprose.";
RL   Biol. Chem. Hoppe-Seyler 375:335-341(1994).
RN   [12]
RP   PROTEIN SEQUENCE OF 41-60.
RX   PubMed=6687683; DOI=10.1016/0006-291x(83)90325-x;
RA   Morii M., Travis J.;
RT   "Structural alterations in alpha 1-antichymotrypsin from normal and acute
RT   phase human plasma.";
RL   Biochem. Biophys. Res. Commun. 111:438-443(1983).
RN   [13]
RP   PROTEIN SEQUENCE OF 48-68 (ISOFORMS 1/2).
RX   PubMed=8647626;
RX   DOI=10.1002/(sici)1097-0215(19960529)66:5<636::aid-ijc10>3.0.co;2-2;
RA   Pinczower G.D., Williams R.P.W., Gianello R.D., Robinson H.C.,
RA   Preston B.N., Linnane A.W.;
RT   "Characterisation of the tumour-associated carbohydrate epitope recognised
RT   by monoclonal antibody 4D3.";
RL   Int. J. Cancer 66:636-644(1996).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 87-129 (ISOFORMS 1/2), AND FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=2404007;
RA   Rubin H., Wang Z., Nickbarg E.B., McLarney S., Naidoo N.,
RA   Schoenberger O.L., Johnson J.L., Cooperman B.S.;
RT   "Cloning, expression, purification, and biological activity of recombinant
RT   native and variant human alpha 1-antichymotrypsins.";
RL   J. Biol. Chem. 265:1199-1207(1990).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 205-423.
RX   PubMed=6547997; DOI=10.1038/311175a0;
RA   Hill R.E., Shaw P.H., Boyd P.A., Baumann H., Hastie N.D.;
RT   "Plasma protease inhibitors in mouse and man: divergence within the
RT   reactive centre regions.";
RL   Nature 311:175-177(1984).
RN   [16]
RP   REACTIVE SITE.
RX   PubMed=6556193;
RA   Morii M., Travis J.;
RT   "Amino acid sequence at the reactive site of human alpha 1-
RT   antichymotrypsin.";
RL   J. Biol. Chem. 258:12749-12752(1983).
RN   [17]
RP   GLYCOSYLATION AT ASN-93 AND ASN-106.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [18]
RP   INTERACTION WITH DNAJC1.
RX   PubMed=14668352; DOI=10.1074/jbc.m310903200;
RA   Kroczynska B., Evangelista C.M., Samant S.S., Elguindi E.C., Blond S.Y.;
RT   "The SANT2 domain of the murine tumor cell DnaJ-like protein 1 human
RT   homologue interacts with alpha1-antichymotrypsin and kinetically interferes
RT   with its serpin inhibitory activity.";
RL   J. Biol. Chem. 279:11432-11443(2004).
RN   [19]
RP   REGION RCL.
RX   PubMed=15638460; DOI=10.1007/s00239-004-2640-9;
RA   Horvath A.J., Forsyth S.L., Coughlin P.B.;
RT   "Expression patterns of murine antichymotrypsin-like genes reflect
RT   evolutionary divergence at the Serpina3 locus.";
RL   J. Mol. Evol. 59:488-497(2004).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-93; ASN-106; ASN-127;
RP   ASN-186 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93; ASN-106; ASN-127 AND
RP   ASN-271.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   GLYCOSYLATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan structures
RT   of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 24-423.
RX   PubMed=2016749; DOI=10.1016/0022-2836(91)90704-a;
RA   Baumann U., Huber R., Bode W., Grosse D., Lesjak M., Laurell C.-B.;
RT   "Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7-A
RT   resolution and its comparison with other serpins.";
RL   J. Mol. Biol. 218:595-606(1991).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 43-423 OF MUTANTS ARG-370 AND
RP   ARG-372.
RX   PubMed=8836107; DOI=10.1038/nsb1096-888;
RA   Lukacs C.M., Zhong J.Q., Plotnick M.I., Rubin H., Cooperman B.S.,
RA   Christianson D.W.;
RT   "Arginine substitutions in the hinge region of antichymotrypsin affect
RT   serpin beta-sheet rearrangement.";
RL   Nat. Struct. Biol. 3:888-893(1996).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 43-423 OF MUTANTS ARG-370; ARG-372
RP   AND ARG-374.
RX   PubMed=9521649; DOI=10.1021/bi972359e;
RA   Lukacs C.M., Rubin H., Christianson D.W.;
RT   "Engineering an anion-binding cavity in antichymotrypsin modulates the
RT   'spring-loaded' serpin-protease interaction.";
RL   Biochemistry 37:3297-3304(1998).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 26-423.
RX   PubMed=10618372; DOI=10.1073/pnas.97.1.67;
RA   Gooptu B., Hazes B., Chang W.-S.W., Dafforn T.R., Carrell R.W., Read R.J.,
RA   Lomas D.A.;
RT   "Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates
RT   two-stage insertion of the reactive loop: implications for inhibitory
RT   function and conformational disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:67-72(2000).
RN   [28]
RP   VARIANT ISEHARA-1 VAL-401.
RX   PubMed=1618300; DOI=10.1016/0014-5793(92)80590-d;
RA   Tsuda M., Sei Y., Yamamura M., Yamamoto M., Shinohara Y.;
RT   "Detection of a new mutant alpha-1-antichymotrypsin in patients with
RT   occlusive-cerebrovascular disease.";
RL   FEBS Lett. 304:66-68(1992).
RN   [29]
RP   VARIANT BONN-1 ALA-252.
RX   PubMed=1351206; DOI=10.1016/0140-6736(92)91301-n;
RA   Poller W., Faber J.-P., Scholz S., Weindinger S., Bartholome K., Olek K.,
RA   Eriksson S.;
RT   "Mis-sense mutation of alpha 1-antichymotrypsin gene associated with
RT   chronic lung disease.";
RL   Lancet 339:1538-1538(1992).
RN   [30]
RP   VARIANT VAL-401.
RX   PubMed=11289720; DOI=10.1007/s100380170125;
RA   Tachikawa H., Tsuda M., Onoe K., Ueno M., Takagi S., Shinohara Y.;
RT   "Alpha-1-antichymotrypsin gene A1252G variant (ACT Isehara-1) is associated
RT   with a lacunar type of ischemic cerebrovascular disease.";
RL   J. Hum. Genet. 46:45-47(2001).
CC   -!- FUNCTION: Although its physiological function is unclear, it can
CC       inhibit neutrophil cathepsin G and mast cell chymase, both of which can
CC       convert angiotensin-1 to the active angiotensin-2.
CC       {ECO:0000269|PubMed:2404007}.
CC   -!- SUBUNIT: Interacts with DNAJC1. {ECO:0000269|PubMed:14668352}.
CC   -!- INTERACTION:
CC       P01011; P05067: APP; NbExp=3; IntAct=EBI-296557, EBI-77613;
CC       P01011; P55212: CASP6; NbExp=3; IntAct=EBI-296557, EBI-718729;
CC       P01011; Q96KC8: DNAJC1; NbExp=3; IntAct=EBI-296557, EBI-296550;
CC       P01011; P13473-2: LAMP2; NbExp=3; IntAct=EBI-296557, EBI-21591415;
CC       P01011; Q9Y371: SH3GLB1; NbExp=3; IntAct=EBI-296557, EBI-2623095;
CC       P01011; Q9UNE7: STUB1; NbExp=3; IntAct=EBI-296557, EBI-357085;
CC       P01011; Q9UBQ0-2: VPS29; NbExp=3; IntAct=EBI-296557, EBI-11141397;
CC       P01011; Q96AX1: VPS33A; NbExp=3; IntAct=EBI-296557, EBI-2527283;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P01011-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01011-2; Sequence=VSP_014227, VSP_014228;
CC       Name=3;
CC         IsoId=P01011-3; Sequence=VSP_014225, VSP_014226;
CC   -!- TISSUE SPECIFICITY: Plasma. Synthesized in the liver. Like the related
CC       alpha-1-antitrypsin, its concentration increases in the acute phase of
CC       inflammation or infection. Found in the amyloid plaques from the
CC       hippocampus of Alzheimer disease brains. {ECO:0000269|PubMed:3257719,
CC       ECO:0000269|PubMed:9880565}.
CC   -!- DOMAIN: The reactive center loop (RCL) extends out from the body of the
CC       protein and directs binding to the target protease. The protease
CC       cleaves the serpin at the reactive site within the RCL, establishing a
CC       covalent linkage between the carboxyl group of the serpin reactive site
CC       and the serine hydroxyl of the protease. The resulting inactive serpin-
CC       protease complex is highly stable.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,
CC       ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.
CC   -!- MISCELLANEOUS: Alpha-1-antichymotrypsin can bind DNA.
CC   -!- SIMILARITY: Belongs to the serpin family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-4 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA51543.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAT08029.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAT08029.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAD92297.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA48671.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-1 antichymotrypsin entry;
CC       URL="https://en.wikipedia.org/wiki/Alpha_1-antichymotrypsin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; K01500; AAA51543.1; ALT_FRAME; mRNA.
DR   EMBL; X68733; CAA48671.1; ALT_INIT; Genomic_DNA.
DR   EMBL; X68734; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68735; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68736; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68737; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; AY513275; AAT08028.1; -; mRNA.
DR   EMBL; AY513276; AAT08029.1; ALT_SEQ; mRNA.
DR   EMBL; AK123091; BAG53869.1; -; mRNA.
DR   EMBL; AB209060; BAD92297.1; ALT_INIT; mRNA.
DR   EMBL; BC003559; AAH03559.3; -; mRNA.
DR   EMBL; BC010530; AAH10530.1; -; mRNA.
DR   EMBL; BC013189; AAH13189.1; -; mRNA.
DR   EMBL; BC034554; AAH34554.1; -; mRNA.
DR   EMBL; BC070265; AAH70265.1; -; mRNA.
DR   EMBL; M18906; AAA51559.1; -; mRNA.
DR   EMBL; AF089747; AAD08810.1; -; mRNA.
DR   EMBL; J05176; AAA51560.1; -; mRNA.
DR   EMBL; X00947; CAA25459.1; -; Genomic_DNA.
DR   CCDS; CCDS32150.1; -. [P01011-1]
DR   PIR; A90475; ITHUC.
DR   PIR; S62374; S62374.
DR   RefSeq; NP_001076.2; NM_001085.4. [P01011-1]
DR   PDB; 1AS4; X-ray; 2.10 A; A=43-383, B=387-423.
DR   PDB; 1QMN; X-ray; 2.27 A; A=26-423.
DR   PDB; 2ACH; X-ray; 2.70 A; A=24-383, B=384-423.
DR   PDB; 3CAA; X-ray; 2.40 A; A=43-383, B=387-423.
DR   PDB; 3DLW; X-ray; 2.70 A; A=25-423.
DR   PDB; 4CAA; X-ray; 2.90 A; A=43-383, B=387-423.
DR   PDB; 6HGE; X-ray; 2.80 A; A/B/C/D=26-423.
DR   PDBsum; 1AS4; -.
DR   PDBsum; 1QMN; -.
DR   PDBsum; 2ACH; -.
DR   PDBsum; 3CAA; -.
DR   PDBsum; 3DLW; -.
DR   PDBsum; 4CAA; -.
DR   PDBsum; 6HGE; -.
DR   SMR; P01011; -.
DR   BioGRID; 106530; 33.
DR   CORUM; P01011; -.
DR   IntAct; P01011; 29.
DR   STRING; 9606.ENSP00000450540; -.
DR   ChEMBL; CHEMBL5960; -.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   MEROPS; I04.002; -.
DR   CarbonylDB; P01011; -.
DR   GlyConnect; 19; 78 N-Linked glycans (5 sites).
DR   GlyGen; P01011; 8 sites, 23 N-linked glycans (5 sites), 2 O-linked glycans (2 sites).
DR   iPTMnet; P01011; -.
DR   PhosphoSitePlus; P01011; -.
DR   BioMuta; SERPINA3; -.
DR   DMDM; 112874; -.
DR   DOSAC-COBS-2DPAGE; P01011; -.
DR   SWISS-2DPAGE; P01011; -.
DR   CPTAC; non-CPTAC-1061; -.
DR   CPTAC; non-CPTAC-1062; -.
DR   EPD; P01011; -.
DR   jPOST; P01011; -.
DR   MassIVE; P01011; -.
DR   MaxQB; P01011; -.
DR   PaxDb; P01011; -.
DR   PeptideAtlas; P01011; -.
DR   PRIDE; P01011; -.
DR   ProteomicsDB; 51303; -. [P01011-1]
DR   ProteomicsDB; 51304; -. [P01011-2]
DR   ProteomicsDB; 51305; -. [P01011-3]
DR   Antibodypedia; 765; 566 antibodies.
DR   DNASU; 12; -.
DR   Ensembl; ENST00000393078; ENSP00000376793; ENSG00000196136. [P01011-1]
DR   Ensembl; ENST00000393080; ENSP00000376795; ENSG00000196136. [P01011-1]
DR   Ensembl; ENST00000467132; ENSP00000450540; ENSG00000196136. [P01011-1]
DR   Ensembl; ENST00000556968; ENSP00000452476; ENSG00000196136. [P01011-2]
DR   GeneID; 12; -.
DR   KEGG; hsa:12; -.
DR   UCSC; uc001ydp.4; human. [P01011-1]
DR   CTD; 12; -.
DR   DisGeNET; 12; -.
DR   GeneCards; SERPINA3; -.
DR   HGNC; HGNC:16; SERPINA3.
DR   HPA; ENSG00000196136; Tissue enriched (liver).
DR   MIM; 107280; gene.
DR   neXtProt; NX_P01011; -.
DR   OpenTargets; ENSG00000196136; -.
DR   Orphanet; 93594; OBSOLETE: Alpha-1-antichymotrypsin deficiency.
DR   PharmGKB; PA35020; -.
DR   VEuPathDB; HostDB:ENSG00000196136.16; -.
DR   eggNOG; KOG2392; Eukaryota.
DR   GeneTree; ENSGT00940000154392; -.
DR   HOGENOM; CLU_023330_2_1_1; -.
DR   InParanoid; P01011; -.
DR   OMA; LCHPNSP; -.
DR   OrthoDB; 131191at2759; -.
DR   PhylomeDB; P01011; -.
DR   TreeFam; TF343201; -.
DR   PathwayCommons; P01011; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SIGNOR; P01011; -.
DR   BioGRID-ORCS; 12; 5 hits in 992 CRISPR screens.
DR   ChiTaRS; SERPINA3; human.
DR   EvolutionaryTrace; P01011; -.
DR   GeneWiki; Alpha_1-antichymotrypsin; -.
DR   GenomeRNAi; 12; -.
DR   Pharos; P01011; Tbio.
DR   PRO; PR:P01011; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P01011; protein.
DR   Bgee; ENSG00000196136; Expressed in liver and 111 other tissues.
DR   ExpressionAtlas; P01011; baseline and differential.
DR   Genevisible; P01011; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0003677; F:DNA binding; TAS:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IBA:GO_Central.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; NAS:UniProtKB.
DR   GO; GO:0030277; P:maintenance of gastrointestinal epithelium; NAS:UniProtKB.
DR   GO; GO:0010951; P:negative regulation of endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; NAS:UniProtKB.
DR   Gene3D; 2.30.39.10; -; 1.
DR   Gene3D; 3.30.497.10; -; 1.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   InterPro; IPR036186; Serpin_sf.
DR   InterPro; IPR042178; Serpin_sf_1.
DR   InterPro; IPR042185; Serpin_sf_2.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Direct protein sequencing;
KW   Disease variant; Glycoprotein; Protease inhibitor; Reference proteome;
KW   Secreted; Serine protease inhibitor; Signal.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000269|PubMed:2787670"
FT   CHAIN           24..423
FT                   /note="Alpha-1-antichymotrypsin"
FT                   /id="PRO_0000032411"
FT   CHAIN           26..423
FT                   /note="Alpha-1-antichymotrypsin His-Pro-less"
FT                   /id="PRO_0000032412"
FT   DNA_BIND        235..237
FT   REGION          369..394
FT                   /note="RCL"
FT   REGION          381..389
FT                   /note="O-glycosylated at one site"
FT   SITE            383..384
FT                   /note="Reactive bond"
FT   CARBOHYD        33
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        93
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        106
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218"
FT   CARBOHYD        127
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        186
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952"
FT   CARBOHYD        271
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16335952,
FT                   ECO:0000269|PubMed:19159218"
FT   VAR_SEQ         64..95
FT                   /note="LVLKAPDKNVIFSPLSISTALAFLSLGAHNTT -> SPRWSIRLCLMYLRRA
FT                   QKHLLPQQSKSPSFLH (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014225"
FT   VAR_SEQ         96..423
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014226"
FT   VAR_SEQ         215..216
FT                   /note="AK -> ER (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_014227"
FT   VAR_SEQ         217..423
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_014228"
FT   VARIANT         9
FT                   /note="A -> T (in dbSNP:rs4934)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3,
FT                   ECO:0000269|Ref.5"
FT                   /id="VAR_006973"
FT   VARIANT         78
FT                   /note="L -> P (in Bochum-1; dbSNP:rs1800463)"
FT                   /evidence="ECO:0000269|PubMed:8244391"
FT                   /id="VAR_006974"
FT   VARIANT         167
FT                   /note="A -> G"
FT                   /id="VAR_006975"
FT   VARIANT         252
FT                   /note="P -> A (in Bonn-1; dbSNP:rs17473)"
FT                   /evidence="ECO:0000269|PubMed:1351206,
FT                   ECO:0000269|PubMed:8244391"
FT                   /id="VAR_006976"
FT   VARIANT         267
FT                   /note="K -> R (in dbSNP:rs17853314)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_037902"
FT   VARIANT         401
FT                   /note="M -> V (associated with occlusive-cerebrovascular
FT                   disease; Isehara-1; dbSNP:rs755521612)"
FT                   /evidence="ECO:0000269|PubMed:11289720,
FT                   ECO:0000269|PubMed:1618300"
FT                   /id="VAR_006977"
FT   VARIANT         407
FT                   /note="D -> G (in dbSNP:rs10956)"
FT                   /id="VAR_011742"
FT   CONFLICT        55
FT                   /note="D -> S (in Ref. 12; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        69
FT                   /note="P -> L (in Ref. 1; AAA51543)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        101
FT                   /note="K -> R (in Ref. 5; BAD92297)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        106
FT                   /note="N -> Y (in Ref. 3; AAT08028)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        198
FT                   /note="D -> N (in Ref. 3; AAT08029)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        199
FT                   /note="L -> P (in Ref. 1; AAA51543)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        234
FT                   /note="S -> N (in Ref. 3; AAT08029)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        339
FT                   /note="S -> G (in Ref. 3; AAT08028)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        346
FT                   /note="I -> S (in Ref. 3; AAT08028)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        361..363
FT                   /note="AVL -> VVS (in Ref. 1; AAA51543)"
FT                   /evidence="ECO:0000305"
FT   HELIX           49..67
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          69..71
FT                   /evidence="ECO:0007744|PDB:1QMN"
FT   STRAND          73..75
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           77..88
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           93..102
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   TURN            107..109
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           112..126
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          130..132
FT                   /evidence="ECO:0007744|PDB:1QMN"
FT   STRAND          134..144
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           151..161
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          164..168
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           170..172
FT                   /evidence="ECO:0007744|PDB:1QMN"
FT   HELIX           173..187
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   TURN            188..190
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          203..219
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           223..225
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          227..234
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          237..256
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   TURN            257..260
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          261..279
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   TURN            281..283
FT                   /evidence="ECO:0007744|PDB:2ACH"
FT   HELIX           284..289
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           293..302
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          304..314
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          316..323
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           325..330
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           335..337
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   HELIX           344..347
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          348..350
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          352..365
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          367..382
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          391..394
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   STRAND          399..405
FT                   /evidence="ECO:0007744|PDB:1AS4"
FT   TURN            406..408
FT                   /evidence="ECO:0007744|PDB:6HGE"
FT   STRAND          412..418
FT                   /evidence="ECO:0007744|PDB:1AS4"
SQ   SEQUENCE   423 AA;  47651 MW;  B002F946C86A8951 CRC64;
     MERMLPLLAL GLLAAGFCPA VLCHPNSPLD EENLTQENQD RGTHVDLGLA SANVDFAFSL
     YKQLVLKAPD KNVIFSPLSI STALAFLSLG AHNTTLTEIL KGLKFNLTET SEAEIHQSFQ
     HLLRTLNQSS DELQLSMGNA MFVKEQLSLL DRFTEDAKRL YGSEAFATDF QDSAAAKKLI
     NDYVKNGTRG KITDLIKDLD SQTMMVLVNY IFFKAKWEMP FDPQDTHQSR FYLSKKKWVM
     VPMMSLHHLT IPYFRDEELS CTVVELKYTG NASALFILPD QDKMEEVEAM LLPETLKRWR
     DSLEFREIGE LYLPKFSISR DYNLNDILLQ LGIEEAFTSK ADLSGITGAR NLAVSQVVHK
     AVLDVFEEGT EASAATAVKI TLLSALVETR TIVRFNRPFL MIIVPTDTQN IFFMSKVTNP
     KQA
//
